Last reviewed · How we verify

Intra-Abdominal Candida Abscess — Treatment Landscape & Competitive Intelligence

Intra-Abdominal Candida Abscess (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Intra-Abdominal Candida Abscess, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Eraxis ANIDULAFUNGIN Vicuron Holdings Echinocandin Antifungal [EPC] 2006-01-01
Cancidas CASPOFUNGIN Merck & Co. Echinocandin Antifungal ATP-binding cassette sub-family G member 2 2001-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Merck & Co. · 1 drug in Intra-Abdominal Candida Abscess
  2. Vicuron Holdings · 1 drug in Intra-Abdominal Candida Abscess

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Intra-Abdominal Candida Abscess:

Cite this brief

Drug Landscape (2026). Intra-Abdominal Candida Abscess — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/intra-abdominal-candida-abscess. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing